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Abstract. The CCN family is a group of extremely cysteine-
rich proteins that are found within the extracellular matrix and 
are comprised of cysteine-rich 61 (Cyr61/CCN1), connective 
tissue growth factor (CTGF/CCN 2) and nephroblastoma over-
expressed (NOV/CCN3). Collectively, these proteins stimulate 
mitosis, adhesion, apoptosis, extracellular matrix production, 
growth arrest and migration, and regulate angiogenesis, 
tumour growth, placentation, implantation, embryogenesis 
and endochondral ossification. Despite such diverse activity, 
CCN protein function has not been explored in human wounds 
and healing. In the present study, we investigated the expres-
sion of these proteins in samples of normal, acute and chronic 
wounds using immunohistochemical staining and real-time 
quantitative RT-PCR. Statistical analysis was performed 
using the Fisher's exact test. Our results showed that, although 
all CCN proteins were present in normal, acute and chronic 
wounds, their expression levels differed, particularly in the 
case of connective tissue growth factor (CTGF), for which 
significantly reduced levels were found in chronic wounds 
compared to acute wounds (p<0.002). Thus, the lack of CTGF 
in wound tissues may contribute to the abnormal healing of 
clinical wounds. This suggests that CCN proteins may play an 
important role in human tissue wound healing. This further 
suggests that human wound healing may be promoted by 
manipulating the levels of this protein.
Introduction
Originally discovered in the early to mid-1990's, members of 
the CCN family are 30- to 40-kDa proteins that are extremely 
cysteine-rich (10% by mass) (1). They are a group of secreted 
proteins that specifically associate with the extracellular 
matrix. They are comprised of cysteine-rich 61 (Cyr61/
CCN1), connective tissue growth factor (CTGF/CCN2) and 
nephroblastoma overexpressed (NOV/CCN3). More recently, 
the Wnt-induced secreted proteins (WISPs) have also been 
found to belong to the CCN family. Thus, WISP-1 has been 
named CCN4, WISP-2 is CCN5 and WISP-3 is CCN6 (1-3). 
Initially it was believed that these proteins were classical 
growth factors. However, following extensive research we 
now appreciate that, although CCN proteins indeed have 
some independent activity, they principally modify the signal-
ling of other molecules (1). Their function is diverse – they 
stimulate mitosis, adhesion, apoptosis, extracellular matrix 
(ECM) production, growth arrest and migration, and regulate 
angiogenesis, tumour growth, placentation, implantation, 
embryogenesis and endochondral ossification (1,2). Target 
cells include fibroblasts, epithelial cells, endothelial cells, 
smooth muscle cells and neuronal cells. CCN proteins have 
a multi-modular mosaic structure, and the diversity in their 
function is thought to be possibly due to the structural hetero-
geneity in this modular configuration (1,2). 
Despite the increased understanding of CCN proteins 
in various biological functions, such as angiogenesis, bone 
remodelling, cancer and endocrine pathways, to our knowl-
edge their effect on human wounds has not previously been 
investigated.
The aim of the present study was to assess the expression 
of CCN family members Cyr61, CTGF and NOV in various 
wounds, and to investigate whether correlations exist between 
the CCN family and the nature of wound healing.
Materials and methods
Materials. Goat anti-human Cyr61, CTGF and NOV antibodies 
were purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA). RNA extraction and RT kits were obtained from 
BioRad (Hemel Hemstead, UK). PCR primers were designed 
using Beacon Designer (Biosoft International, Palo Alto, CA, 
USA) and synthesized by Sigma Genesis (Poole, Dorset, UK). 
Molecular biology-grade agarose and the DNA ladder were 
obtained from Invitrogen. Mastermix for the routine and quan-
titative PCR was from Sigma and BioRad, respectively.
Skin biopsies. Fresh frozen skin biopsies were retrieved 
from the departmental tissue bank and processed as previ-
ously reported (4,5). These samples were collected with the 
approval of the South East Wales Local Research Ethics 
Committee and stored in accordance to the Human Tissue Act 
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(www.hta.gov.uk). Samples used included normal skin, acute 
wound tissue and chronic wound tissue.
Normal skin. In order to obtain a comparison with wound 
tissue, unwounded skin was analysed. Unwounded skin 
samples were obtained from 10 healthy staff members in our 
department. Under local anaesthesia, a 3-mm punch biopsy 
was extracted from the inner region of the upper arm.
Acute wound tissue. Single punch biopsies were obtained 
from 10 patients with acute wounds after undergoing excision 
of pilonidal disease. These wounds were judged to be clini-
cally non-infected by a medical wound healing expert from a 
specialist wound healing unit. These biopsies were obtained 
from the wound margin incorporating the epidermis and dermis 
at the wound edge within 6 weeks from the surgical excision.
Chronic wound tissue. Seventeen patients with chronic venous 
leg ulcers (present for >6 months) showing no sign of healing 
for a duration of 6 weeks were biopsied. Duplex ultrasonog-
raphy was used to confirm venous disease. These wounds 
were judged to be clinically non-infected by a medical wound 
healing expert from a specialist wound healing unit. Again 
biopsies were obtained from the wound margin incorporating 
the epidermis and dermis at the wound edge.
Immunohistochemical staining. Immunohistochemical staining 
was performed using a standard technique employed in our 
laboratories (3,4). The tissues were frozen-sectioned using 
a Leica cryostat, at an 8-µm thickness. The sections were 
mounted on Super Frost Plus microscope slides, air dried and 
then fixed in acetone (Fisher Scientific Ltd., Loughborough, 
UK) for 15 min. Excess acetone was removed by air drying 
the sections for 10 min before being washed three times in 
Tris-buffered saline (TBS) for 5 min each time. Endogenous 
peroxidase was blocked by further treating the slides in the 
blocking solution (5 ml of 30% H2O2 in 300 ml pure ethanol) 
for 15 min. Following rehydration, sections were incubated 
at room temperature with normal blocking solution which 
contained horse serum (Dako Ltd., High Wycombe, UK). 
Excess blocking serum was removed, and the sections 
were probed with the working dilution of primary antibody 
(produced in 1% TBS/BSA, dilution 1:150). 
Antibody localisation was subsequently identified 
using a standard streptavidin-biotin peroxidase technique 
using the Vector Elite ABC kit (Vector Laboratories). This 
involved incubation with a biotinylated secondary antibody 
for 30 min, followed by incubation for an additional 30 min 
with the avidin-biotin complex reagent provided in the kit. 
Diaminobenzidine (DAB) (0.005%) was then added to the 
sections, which were incubated in the dark for 5 min. The 
sections were then rinsed in TBS, followed by tap water and 
then counterstained with Ehrlrich's haematoxylin solution 
(BDH-Merck, Poole, UK) for 30 sec and then washed again 
in tap water for 5 min. The sections were then dehydrated 
through a graded series of alcohol solutions (BDH-Merck) and 
mounted in DPX medium (BDH-Merck) under a coverslip.
Positive staining was noted as a brown deposit, and non-
stained cells as blue counterstained nucleated cells with no 
associated brown DAB stain. Images were obtained using 
a digital camera. Slides were evaluated by two independent 
researchers.
RNA extraction and complimentary DNA (cDNA) synthesis. 
Individual biopsies were rapidly thawed and homogenised 
using the Ultra-Turrax T8 (IKA Labortechnik, Staufen, 
Germany) in RNA extraction buffer (AbGene). Total cellular 
RNA was quantified using a spectrophotometer (WPA UV 
1101; Biotech Photometer, Cambridge, UK). Reverse tran-
scriptase was performed using 0.5 µg of the RNA sample 
using oligo-dT primer according to the manufacturer's 
instructions and a reverse transcription kit (Sigma, Poole, 
Dorset, UK). cDNA was prepared by heating the samples at 
47˚C for 60 min, followed by incubation at 75˚C for 10 min to 
inactivate any reverse transcriptase.
Quantitative analysis of CCN family members. The transcript 
levels of the CCN family members from the prepared cDNA 
were determined using a real-time quantitative PCR, based 
on the Ampliflour™ technology to determine the expression 
levels of Cyr61, CTGF, NOV and GAPDH transcripts in acute 
and chronic wound tissue and in normal skin. The primers 
used are listed in Table I. 
The reaction was carried out using conditions as previously 
reported (6,7): Hot-Start Q-Mastermix (Abgene), 10 pmol 
of specific forward primer, 10 pmol of reverse primer which 
Table I. PCR primers used.
Cyr61 5'-GGGCTGGAATGCAACTTC-3'
 5'-AACTGAACCTGACCGTACACGTTTTGGTAGATTCTGGAG-3'
 (spanning the third intron; GenBank accession no. AF307860)
CTGF 5'-GAGTGGGTGTGTGACGAG-3'
 5'-ACTGAACCTGACCGTACAGGCAGTTGGCTCTAATCATA-3' 
 (spanning the fourth intron; NM_001901)
NOV 5'-CTGTGAACAAGAGCCAGAG-3'
 5'-ACTGAACCTGACCGTACACTTGAACTGCAGGTGGAT-3'
 (spanning positions 848-849; NM-002514)
GAPDH 5'-CTGAGTACGTCGTGGAGTC-3' 
 5'-ACTGAACCTGACCGTACACAGAGATGACCCTTTTG-3'
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contains the Z sequence, 100 pmol of 6 carboxyfluorescein 
(FAM)-tagged probe (Integren), and cDNA from ~50 ng RNA 
(calculated from the initial RNA in the reverse transcriptase 
reaction). The reaction was carried out using IcyclerIQ™ 
(BioRad) which was equipped with an optic unit that allowed 
real-time detection of 96 reactions using the following condi-
tions: 94˚C for 12 min, 50 cycles at 94˚C for 15 sec, 55˚C for 
40 sec and 72˚C for 20 sec. The levels of the transcripts were 
generated from an internal standard (8) that was simultane-
ously amplified with the samples.
Results
Protein expression of CCN family members in acute and 
chronic wound tissues and normal skin tissue. The staining 
pattern of CCN family members was evaluated according to the 
spatial distribution. Subdivisions of skin adjacent to the wound 
edge (WE) and 2 mm from the wound edge moving towards 
normal skin were analysed in acute and chronic wounds to allow 
comparison of the dermis at intervals from the wound bed. 
Cyr61. In normal skin, Cyr61 staining was found to be most 
intense in the dermal layer of the skin. In acute wounds 
this staining of the dermal layer of the skin was unaltered. 
However, in chronic wounds the staining in the dermal layer 
was increased, i.e., was more intensely stained possibly 
suggesting increased levels of Cyr61 (Fig. 1A).
CTGF. In normal skin, CTGF staining was found to be most 
intense in the dermal layer of the skin. However, in compar-
Figure 1. Immunohistochemical staining of Cyr61/CCN1, CTGF/CCN2 and NOV/CCN3. (A) Cyr61 staining: a, acute wound - wound edge; b, acute wound 
- 2 mm from wound edge in direction towards normal skin; c, chronic wound - wound edge; d, chronic wound - 2 mm from wound edge in direction towards 
normal skin; e, normal skin. (B) CTGF/CCN2 staining: a, acute wound - wound edge; b, acute wound - 2 mm from wound edge in direction towards normal 
skin; c, chronic wound - wound edge; d, chronic wound - 2 mm from wound edge in direction towards normal skin; e, normal skin. (C) NOV/CCN3 staining: 
a, acute wound - wound edge; b, acute wound - 2 mm from wound edge in direction towards normal skin; c, chronic wound - wound edge; d, chronic wound - 
2 mm from wound edge in direction towards normal skin; e, normal skin.
  A
  B
  C
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ison to Cyr61, the level of staining was weaker. In acute 
wounds, the staining of the dermal layer was again weaker 
and even weaker in chronic wounds possibly suggesting the 
loss of CTGF (Fig. 1B). 
NOV. In normal skin, NOV staining was found to be most 
intense in the dermal layer of the skin. However, similar to 
CTGF, the staining in comparison to Cyr61 was weaker. In 
acute and chronic wounds, staining of the dermal layer of the 
skin was unaltered, possibly suggesting no change in NOV 
expression in the wounded states (Fig. 1C). 
Analysis of CCN mRNA in normal skin, acute and chronic 
wound tissues. Both conventional RT-PCR and quantitative 
real-time RT-PCR were used to analyze the presence and 
quantity of messages of Cyr61/CCN1, CTGF/CCN2 and NOV/
CCN3. Comparisons were made between acute and chronic 
wound tissues. 
Over 70% of the chronic wound tissues showed a high 
level of Cyr61 compared to 40% of the acute wounds. The 
difference was nonetheless not statistically significant 
(p=0.13) (Table II). The most significant finding was the levels 
of CTGF/CCN2 in chronic wounds. All (14/14) of the chronic 
tissues were found to exhibit low levels of the CTGF/CCN2 
transcript, compared to only 60% of acute wounds (p=0.0016; 
Table III). A trend similar to CTGF/CCN2 was observed for 
NOV/CCN3; a higher percentage of chronic wound tissues had 
low levels of the NOV transcript, although this did not reach 
statistical significance (p=0.075; Table IV). 
Discussion
Non-healing wounds cause great distress to both patients and 
health professionals. It is estimated that chronic wounds cost 
the NHS £2.3-3.1 billion/year in the UK (9). Therefore, iden-
tifying factors which cause wounds to become chronic may 
result in the development of possible future therapeutic targets. 
The present study demonstrated a differential expression of 
Cyr61/CCN1, CTGF/CCN2 and NOV/CCN3 in acute wound 
tissue, chronic wound tissue and normal skin particularly for 
CTGF/CCN2. 
The most important finding in the present study was the 
significant change in CTGF/CCN2 expression in chronic 
wounds. Virtually all of the tissues showed low levels of 
CTGF/CCN2 expression. CTGF/CCN2, also known as 
insulin-like growth factor binding protein-8 (IGFBP8), was 
initially identified from endothelial cells and is thought to 
play a role in connective tissue biology (10). Similar to other 
IGFBPs, CTGF/CCN2 is known to be involved in the action 
of IGF (10). Cyr61/CCN1, CTGF/CCN2 and NOV/CCN3 
were also found to be induced during tissue repair in adults; 
however, no comparisons of their expression levels have been 
evaluated in acute and chronic wound tissues. Elevated levels 
of CTGF/CCN2 were also found to be a hallmark of fibrosis 
(2,10). It has been suggested that an inappropriate overexpres-
sion of CTGF/CCN2 creates an environment allowing other 
stimuli to induce potent fibrotic responses (9). It has also been 
postulated that CTGF/CCN2 is required for maximal adhesive 
signalling in fibroblasts undergoing active tissue remodelling, 
such as in embryogenesis, fibrotic cells or tumour cells (10). 
Therefore, it would follow that underexpression of CTGF/
CCN2 creates an environment that impedes wound healing 
and lack of adhesive signalling in fibroblasts leading to 
chronicity of wounds as suggested in the present study. This 
important finding further suggests a therapeutic role of CTGF 
in chronic wound healing.
Notably, NOV/CCN3 is also present at low levels in chronic 
wound tissues. Initially discovered from myeloblastosis-asso-
ciated virus-induced nephroblastoma, the molecule also shares 
some homology with the IGFBP family (11). Although the 
functions of NOV/CCN3 are not clear, it has been suggested 
that the molecule is a keen regulator of haematopoietic stem 
cells and is associated with tumourigenicity in animal models 
(12). The result from the present study, although they did not 
reach statistical significance (due largely to a small sample 
size), points to a potential role of NOV in abnormal wound 
healing. This finding warrants further investigation. Although 
Cyr61/CCN1 has been shown to be strongly linked to cell 
migration, matrix adhesion and angiogenesis (1,2), one reason 
to examine this family further is that the present study failed 
Table II. Expression of Cyr61/CCN1 transcript in wound tissues.
 Normal Acute wound Chronic wound
 skin tissue tissue
 n=10 n=10 n=14
High 4 4 10
Low 6 6   4
Acute wound tissue vs. chronic wound tissue, p=0.13, by Fisher's 
exact test.
Table III. Expression of CTGF/CCN2 transcript in wound tissues.
 Normal Acute wound Chronic wound
 skin tissue tissue
 n=10 n=10 n=14
High 7 6   0
Low 3 4 14
Acute wound tissue vs. chronic wound tissue, p=0.0016, by Fisher's 
exact test.
Table IV. Expression of NOV/CCN3 transcript in wound tissues.
 Normal Acute wound Chronic wound
 skin tissue tissue
 n=10 n=10 n=14
High 1 5   2
Low 9 5 12
Acute wound tissue vs. chronic wound tissue, p=0.075, by Fisher's 
exact test.
EXPERIMENTAL AND THERAPEUTIC MEDICINE  2:  641-645,  2011 645
to show such a connection. In contrast to our initial hypothesis 
that this factor may be reduced in chronic wounds, and in 
clear contrast to CTGF/CCN2 and NOV/CCN3, Cyr61/CCN1 
appeared to be present at marginally higher levels in chronic 
wounds. Although this must be further confirmed in a larger 
study, it does indicate that Cyr61/CCN1 may have a differen-
tial role in the healing process. 
In conclusion, the present study demonstrated that CTGF/
CCN2 and NOV/CCN3, to a smaller extent, are aberrantly 
expressed in wound tissues and are linked to the outcome of 
clinical wound healing. The findings from the present study 
indicate that these molecules are potential therapeutic targets 
in chronic wound healing.
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